Bioregenx (BRGX) Invested Capital (2021 - 2026)

Bioregenx has reported Invested Capital for 6 years, with the latest figure at -$4.4 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital fell 80.17% year-over-year to -$4.4 million; the trailing twelve-month figure through Mar 2026 stood at -$4.4 million (down 80.17% YoY), and the FY2025 full-year result was -$4.4 million, down 94.92% from the prior year.
• Invested Capital for Q1 2026 stood at -$4.4 million, roughly flat from -$4.4 million in the prior quarter.
• The five-year high for Invested Capital was $16.0 million in Q1 2024, with the low at -$4.4 million in Q4 2025.
• Average Invested Capital over 5 years is $899852.3, with a median of -$2.2 million recorded in 2024.
• Year-over-year, Invested Capital tumbled 2110.9% in 2022 and jumped 824.46% in 2024.
• Tracing BRGX's Invested Capital over 5 years: stood at -$2.3 million in 2022, then surged by 33.6% to -$1.5 million in 2023, then sank by 45.0% to -$2.2 million in 2024, then tumbled by 94.92% to -$4.4 million in 2025, then climbed by 0.16% to -$4.4 million in 2026.
• The last three Invested Capital figures came in at -$4.4 million (Q1 2026), -$4.4 million (Q4 2025), and -$2.6 million (Q3 2025), per Business Quant data.

Peer Comparison